Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Inclusion Criteria:

• Histologically or cytologically confirmed NSCLC (either nonsquamous or squamous)that is Stage IV (AJCC v8).

• No prior systemic treatment for the advanced/metastatic NSCLC

• Able to provide a formalin-fixed archival tumor tissue sample during screening, or afresh tumor biopsy

• Measurable disease per RECIST v1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Life expectancy of at least 3 months.

• Willingness to avoid pregnancy or fathering children.

• Adequate organ function as indicated by protocol-specified laboratory values. - Hasbeen fully vaccinated against SARS-CoV-2 or is willing and able to be fullyvaccinated against SARS-CoV-2 during the study by starting the vaccination processduring screening.

Exclusion Criteria:

• Clinically significant cardiac disease within 6 months of start of study treatment.

• Any major surgery within 3 weeks of the first dose of study treatment.

• Thoracic radiation therapy of > 30 Gy within 6 months of the first dose of studytreatment.

• History of peripheral neuropathy ≥ Grade 2 CTCAE v5 for participants who may receivecisplatin, paclitaxel, or nab-paclitaxel.

• Untreated central nervous system metastases and/or carcinomatous meningitis.

• Evidence or history of interstitial lung disease or noninfectious pneumonitis thatrequired systemic steroids.

• Active infection requiring systemic therapy or active tuberculosis. Note: Ifrequired by country or local regulations to be tested for COVID-19 during screening,a participant should be excluded if they have a positive test result for SARS CoV-2infection until both the retesting result is negative and clinical recovery isobtained.

• Superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervicalcancer, or other in situ cancers.

• Has contraindications to chemotherapy agents used in the study.

• Has an active autoimmune disease that has required systemic treatment in past 2years.

• Is receiving systemic antibiotics or steroid therapy ≤ 7 days prior to the firstdose of study treatment.

• Has received a live vaccine within 30 days before the first dose of study treatment (and until 90 days after last dose of study drug).

Note: While based on approved SARS-CoV-2 vaccines available worldwide, many vaccines are not live (mRNA and adenovirus vaccines do not contain live virus), if a live vaccine against SARS-CoV-2 is the only available option, prior consultation with the medical monitor should be obtained.

• Has known active HBV or HCV (testing must be performed to determine eligibility)